New Sesquiterpenoids with Hypolipidemic Activities from An Edible-medicinal Fungi Irpex lacteus

Zhenke Zhu,Fan-Dong Kong,Yue Lü,Ying Liu,Mingguo Jiang,Liu Hongcun,Yang Xiao,Lifang Yang
DOI: https://doi.org/10.21203/rs.3.rs-3035658/v1
2023-01-01
Abstract:Abstract Twelve sesquiterpenoids, including four azulenoids (compounds 4, 5, 8, 12), five monocyclic sesquiterpenoids (compounds 1, 2, 6, 10, 11) were isolated from an edible-medicinal fungi Irpex lacteus. Compounds 1-8 were new compounds and compounds 9-12 were known but first found in Irpex lacteus. The structure of compound 1-8 were established by combining spectroscopic methods, including integrated NMR, MS, UV, IR, and ECD calculations. All of the isolated compounds(1−12) were evaluated for hypolipidemic activity by a commercially available assay kit. All dose groups of compound 2, 4, 6 and 12, compound 1, 5, 7, 9, 10, 11 (50 and 100 μg/mL) and compound 3, 8 (100 μg/mL) exhibited betterdecreased (P<0.01, P<0.05) the TG activity than the positive control lovastatin (100 μg/mL). Especially, compound 6 showed the highest hypolipidemic activity in 12 compounds, which decreased TG by 54.69% (100 μg/mL), 42.19% (50 μg/mL) and 34.38% (25 μg/mL), respectively.
What problem does this paper attempt to address?